Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 4/2015

01-04-2015 | New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Preoperative Imaging for Staging Bladder Cancer

Authors: Maxim J. McKibben, Michael E. Woods

Published in: Current Urology Reports | Issue 4/2015

Login to get access

Abstract

Accurate preoperative staging of bladder cancer is essential in determining the extent of disease and optimal treatment. The current gold standard of transurethral resection of bladder tumor (TURBT) followed by computed tomography (CT) imaging provides excellent staging specificity, but often understages the disease, leading to pathologic upstaging and adverse outcomes in patients undergoing radical cystectomy. Newer imaging modalities, such as multiparametric magnetic resonance (MR) imaging and positron emission tomography (PET) combined with CT or MR provides promising imaging alternatives which may improve accuracy of staging both local and distant disease.
Literature
1.
2.
Clark P. NCCN clinical practice guidelines in oncology: bladder cancer - version 2. 2014.
3.
Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.CrossRefPubMed
4.
Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007;51(1):137–51.CrossRefPubMed
5.
Tritschler S, Mosler C, Straub J, et al. Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment? World J Urol. 2012;30(6):827–31.CrossRefPubMed
6.
Gray PJ, Lin CC, Jemal A, et al. Clinical–pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys. 2014;88(5):1048–56.CrossRefPubMed
7.
Bostrom PJ, van Rhijn BW, Fleshner N, et al. Staging and staging errors in bladder cancer. Eur Urol Suppl. 2010;9(1):2–9.CrossRef
8.
Liedberg F, Bendahl PO, Davidsson T, et al. Preoperative staging of locally advanced bladder cancer before radical cystectomy using 3 tesla magnetic resonance imaging with a standardized protocol. Scand J Urol. 2013;47(2):108–12.
9.
Barentsz J, Engelbrecht M, Witjes J, De la Rosette J, Van der Graaf M. MR imaging of the male pelvis. Eur Radiol. 1999;9(9):1722–36.CrossRefPubMed
10.
Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163(6):1693–6.CrossRefPubMed
11.
El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion-and T2-weighted MR imaging. Eur Radiol. 2009;19(7):1575–81.CrossRefPubMed
12.
Kundra V, Silverman PM. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. Am J Roentgenol. 2003;180(4):1045–54.CrossRef
12.••
de Haas RJ, Steyvers MJ, Fütterer JJ. Multiparametric MRI of the bladder: ready for clinical routine? Am J Roentgenol. 2014;202(6):1187–95. An excellent review of recent studies of the multiparametric MR imaging in bladder cancer, with clear explanations of various MR techniques and their strengths and weaknesses.CrossRef
14.
Tekes A, Kamel IR, Imam K, Chan TY, Schoenberg MP, Bluemke DA. MR imaging features of transitional cell carcinoma of the urinary bladder. Am J Roentgenol. 2003;180(3):771–7.CrossRef
15.
Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology. 1994;193(1):239–45.CrossRefPubMed
15.••
Daneshmand S, Ahmadi H, Huynh LN, Dobos N. Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology. 2012;80(6):1313–8. The largest prospective study to date of bladder cancer T and N staging using dynamic contrast-enhanced MR.CrossRefPubMed
17.
Tekes A, Kamel I, Imam K, et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. Am J Roentgenol. 2005;184(1):121–7.CrossRef
18.
Tuncbilek N, Kaplan M, Altaner S, et al. Value of dynamic contrast-enhanced MRI and correlation with tumor angiogenesis in bladder cancer. Am J Roentgenol. 2009;192(4):949–55.CrossRef
19.
20.
20.•
Nguyen HT, Jia G, Shah ZK et al. Prediction of chemotherapeutic response in bladder cancer using k‐means clustering of dynamic contrast‐enhanced (DCE)‐MRI pharmacokinetic parameters. J Magn Reson Imaging. 2014. Pilot study evaluating DCE-MR characteristics as a surrogate for tumor blood flow in assessing early response to chemotherapy. Further studies may provide early guidance in management of patients undergoing neoadjuvant chemotherapy.
22.
23.
Yoshida S, Koga F, Kobayashi S, et al. Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy. World J Radiol. 2014;6(6):344.CrossRefPubMedCentralPubMed
24.
Papalia R, Simone G, Grasso R, et al. Diffusion‐weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases. BJU Int. 2012;109(7):1031–6.CrossRefPubMed
25.
Sevcenco S, Ponhold L, Heinz-Peer G et al. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. 2014.
25.•
Kobayashi S, Koga F, Kajino K, et al. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Magn Reson Imaging. 2014;39(1):172–8. Confirms DW-MR characteristics correlate with bladder cancers’ biologic aggressiveness.CrossRefPubMed
27.
Chen C, Li C, Kuo Y, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants—initial experience 1. Radiology. 2006;239(2):448–56.CrossRefPubMed
28.
Cui Y, Zhang X, Sun Y, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases 1. Radiology. 2008;248(3):894–900.CrossRefPubMed
29.
Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol. 2008;111(2):213–20.CrossRefPubMed
30.
Kyriazi S, Collins DJ, Messiou C, et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging—value of histogram analysis of apparent diffusion coefficients. Radiology. 2011;261(1):182–92.CrossRefPubMed
31.
Deserno WM, Harisinghani MG, Taupitz M, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10–enhanced MR imaging 1. Radiology. 2004;233(2):449–56.CrossRefPubMed
31.•
Birkhäuser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall superparamagnetic particles of iron oxide–enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol. 2013;64(6):953–60. Pilot study combining DW-MR and lymphotrophic nanoparticle-enhanced MR in clinical staging of bladder, demonstrating excellent accuracy in staging bladder cancer.CrossRefPubMed
33.
Lu Y, Chen J, Liang J, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2012;81(9):2411–6.CrossRefPubMed
34.
35.
36.
37.
Jadvar H, Quan V, Henderson RW, Conti PS. [F-18]-fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 2008;13(1):42–7.CrossRefPubMedCentralPubMed
38.
Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32(12):1412–7.CrossRefPubMed
38.••
Goodfellow H, Viney Z, Hughes P, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)‐computed tomography (CT) in the staging of bladder cancer. BJU Int. 2014;114(3):389–95. The largest head-to-head comparison to date of CT versus PET/CT for staging bladder cancer. Demonstrates modest staging benefit with PET/CT.PubMed
40.
Liu IJ, Lai YH, Espiritu JI, et al. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int. 2006;77(1):69–75.CrossRefPubMed
41.
Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med. 2007;48(5):764–70.CrossRefPubMed
42.
Schöder H, Ong SC, Reuter VE, et al. Initial results with 11C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol. 2012;14(2):245–51.CrossRefPubMed
43.
Picchio M, Treiber U, Beer AJ, et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med. 2006;47(6):938–44.PubMed
44.
Maurer T, Souvatzoglou M, Kübler H, et al. Diagnostic efficacy of [11C] choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 2012;61(5):1031–8.CrossRefPubMed
45.
Ahlström H, Malmström P, Letocha H, Andersson J, Långström B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol. 1996;37(2):180–5.CrossRefPubMed
46.
Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45(2):272–8.PubMed
47.
Hillner BE, Siegel BA, Hanna L, et al. Impact of 18F-fluoride PET on intended management of patients with cancers other than prostate cancer: results from the national oncologic PET registry. J Nucl Med. 2014;55(7):1054–61.CrossRefPubMed
48.
49.
Orlova A, Tran TA, Ekblad T, Karlström AE, Tolmachev V. 186Re-maSGS-ZHER2: 342, a potential affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging. 2010;37(2):260–9.CrossRefPubMed
50.
Kjær A, Loft A, Law I, et al. PET/MRI in cancer patients: first experiences and vision from Copenhagen. MAGMA. 2013;26(1):37–47.CrossRefPubMed
51.
Partovi S, Robbin MR, Steinbach OC, et al. Initial experience of MR/PET in a clinical cancer center. J Magn Reson Imaging. 2014;39(4):768–80.CrossRefPubMed
51.•
Li Q, Tang J, He E, et al. Clinical utility of three-dimensional contrast-enhanced ultrasound in the differentiation between noninvasive and invasive neoplasms of urinary bladder. Eur J Radiol. 2012;81(11):2936–42. Small study comparing 3D CE-US to 3D US and CE-US alone, demonstrating good accuracy in clinical staging of the primary bladder cancer.CrossRefPubMed
53.
Park HJ, Hong SS, Kim JH, et al. Tumor detection and serosal invasion of bladder cancer: role of three-dimensional volumetric reconstructed US. Abdom Imaging. 2010;35(3):265–70.CrossRefPubMed
54.
Caruso G, Salvaggio G, Campisi A, et al. Bladder tumor staging: comparison of contrast-enhanced and gray-scale ultrasound. Am J Roentgenol. 2010;194(1):151–6.CrossRef
55.
Xu C, Zhang Z, Wang H, et al. A new tool for distinguishing muscle invasive and non-muscle invasive bladder cancer: the initial application of flexible ultrasound bronchoscope in bladder tumor staging. PLoS One. 2014;9(4):e92385.CrossRefPubMedCentralPubMed
Metadata
Title
Preoperative Imaging for Staging Bladder Cancer
Authors
Maxim J. McKibben
Michael E. Woods
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Urology Reports / Issue 4/2015
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-015-0496-8

Other articles of this Issue 4/2015

Current Urology Reports 4/2015 Go to the issue

Men’s Health (R Carrion and C Yang, Section Editors)

Strategies for Penile Prosthesis Placement in Peyronie’s Disease and Corporal Fibrosis

Urothelial Cancer (A Sagalowsky, Section Editor)

Preoperative and Modifiable Factors to Lower Postoperative Complications After Radical Cystectomy

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Post Partial Nephrectomy Surveillance Imaging: an Evidence-Based Approach

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Contemporary Assessment of Renal Stone Complexity Using Cross-Sectional Imaging

Prostate Cancer (A Kibel, Section Editor)

Active Surveillance for Low-Risk Prostate Cancer

Urothelial Cancer (A Sagalowsky, Section Editor)

New Perioperative Fluid and Pharmacologic Management Protocol Results in Reduced Blood Loss, Faster Return of Bowel Function, and Overall Recovery